[
  {
    "ts": null,
    "headline": "Buffett’s 1994 Advice That Still Destroys Most Investors’ Portfolios: He’d Rather ‘Own a Significant Portion of the Hope Diamond than 100% of a Rhinestone’",
    "summary": "Warren Buffett warns investors it's better to own a smaller portion of a good thing than the entirety of something worthless.",
    "url": "https://finnhub.io/api/news?id=aed9f3bcbeb0b1634ceff2a40f1f4aa83e12683cd6ab0a242840779c0909a5c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769791620,
      "headline": "Buffett’s 1994 Advice That Still Destroys Most Investors’ Portfolios: He’d Rather ‘Own a Significant Portion of the Hope Diamond than 100% of a Rhinestone’",
      "id": 138308866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WFC",
      "source": "Yahoo",
      "summary": "Warren Buffett warns investors it's better to own a smaller portion of a good thing than the entirety of something worthless.",
      "url": "https://finnhub.io/api/news?id=aed9f3bcbeb0b1634ceff2a40f1f4aa83e12683cd6ab0a242840779c0909a5c5"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo to pay CEO Scharf $40M for 2025",
    "summary": "The bank credited Charlie Scharf for the resolution of seven consent orders last year, including a $1.95 trillion asset cap imposed by the Federal Reserve.",
    "url": "https://finnhub.io/api/news?id=106de33e7fc2df88d6d31b59fc2df6f0a15c8e4763468f316c907042fcdccad4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769775324,
      "headline": "Wells Fargo to pay CEO Scharf $40M for 2025",
      "id": 138307337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WFC",
      "source": "Yahoo",
      "summary": "The bank credited Charlie Scharf for the resolution of seven consent orders last year, including a $1.95 trillion asset cap imposed by the Federal Reserve.",
      "url": "https://finnhub.io/api/news?id=106de33e7fc2df88d6d31b59fc2df6f0a15c8e4763468f316c907042fcdccad4"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo launches internal proxy voting service",
    "summary": "The bank’s investment management arm becomes the second major asset manager to ditch third-party proxy advisory firms for a proprietary service.",
    "url": "https://finnhub.io/api/news?id=7e9cb785848f65573d80204edcbf498b4be87fcd4f661ba5fe583f36c253b7c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769773920,
      "headline": "Wells Fargo launches internal proxy voting service",
      "id": 138307338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WFC",
      "source": "Yahoo",
      "summary": "The bank’s investment management arm becomes the second major asset manager to ditch third-party proxy advisory firms for a proprietary service.",
      "url": "https://finnhub.io/api/news?id=7e9cb785848f65573d80204edcbf498b4be87fcd4f661ba5fe583f36c253b7c5"
    }
  },
  {
    "ts": null,
    "headline": "Is Wells Fargo (WFC) Pricing Reflect Its Recent 17.5% One Year Share Gain",
    "summary": "If you are wondering whether Wells Fargo's current share price reflects real value or just headline noise, this article will walk through what the numbers say about the stock. At a last close of US$90.64, the stock has returned 3.0% over the past week, while the 30 day and year to date returns of a 3.9% decline and a 4.8% decline contrast with a 17.5% return over the last year. Recent coverage on Wells Fargo has focused on its position among major US banks and how investors are weighing...",
    "url": "https://finnhub.io/api/news?id=ddfee04e6c24adacf6191511a20e357582221f65a341ba0a327274970d248795",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769764489,
      "headline": "Is Wells Fargo (WFC) Pricing Reflect Its Recent 17.5% One Year Share Gain",
      "id": 138304035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WFC",
      "source": "Yahoo",
      "summary": "If you are wondering whether Wells Fargo's current share price reflects real value or just headline noise, this article will walk through what the numbers say about the stock. At a last close of US$90.64, the stock has returned 3.0% over the past week, while the 30 day and year to date returns of a 3.9% decline and a 4.8% decline contrast with a 17.5% return over the last year. Recent coverage on Wells Fargo has focused on its position among major US banks and how investors are weighing...",
      "url": "https://finnhub.io/api/news?id=ddfee04e6c24adacf6191511a20e357582221f65a341ba0a327274970d248795"
    }
  },
  {
    "ts": null,
    "headline": "UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect",
    "summary": "Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential. On January 7, UBS assumed coverage of Arcellx with a Buy rating and $100 price target as the firm assumed coverage on 22 small-to-mid cap biotech names. Contending that biotech fundamentals are now inflecting after a rough period, UBS […]",
    "url": "https://finnhub.io/api/news?id=fbc25a34b6c29a5bb6de8b48dcb2facf454ff4a0d03bcf3852520d909bee8fe6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769750652,
      "headline": "UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect",
      "id": 138303000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WFC",
      "source": "Yahoo",
      "summary": "Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential. On January 7, UBS assumed coverage of Arcellx with a Buy rating and $100 price target as the firm assumed coverage on 22 small-to-mid cap biotech names. Contending that biotech fundamentals are now inflecting after a rough period, UBS […]",
      "url": "https://finnhub.io/api/news?id=fbc25a34b6c29a5bb6de8b48dcb2facf454ff4a0d03bcf3852520d909bee8fe6"
    }
  }
]